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Abstract
Background: As has occurred in many regions worldwide, in 2012 the incidence of pertussis increased in Perú.
This epidemiologic situation has been associated with a waning vaccine-induced immunity and the adaptation
of Bordetella pertussis to vaccine-induced immunity along with improved diagnostic methods.
Methods: The study comprised a total of 840 pertussis-suspected cases reported in Perú during 2012. We
summarize here the distribution of pertussis cases according to age and immunization status along with the
immunization-coverage rate. Laboratory diagnosis was performed by culture test and real-time polymerase-chain
reaction (PCR). B. pertussis bacteria recovered from infected patients were characterized by pulsed-field gel
electrophoresis (PFGE), and the DNA sequencing of the pertussis-toxin (promoter and subunit A), pertactin, and
fimbriae (fim2 and fim3) genes.
Results: From the total pertussis-suspected cases, 191 (22.7 %) infections were confirmed by real-time PCR and 18
through cultivation of B. pertussis (2.1 %), while one infection of B. parapertussis (0.11 %) was also detected by
culture. Pertussis was significantly higher in patients that had had 0–3 vaccine doses (pentavalent vaccine alone)
than in those who had had 4–5 vaccine doses (pentavalent plus DwPT boosters) at 94.3 vs. 5.7 %, respectively
(p < 0.00001). The relative risk (RR) for patients with 4–5 doses compared to those with fewer than 4 doses or no
dose was 0.23 (95 % Confidence Interval: 0.11–0.44), while the vaccine effectiveness was 77 % and coverage 50.5 %.
Genetic analysis of B. pertussis isolates from different Peruvian regions detected two clonal groups as identified by
PFGE. Those two groups corresponded to the B. pertussis genotypes emerging worldwide ptxP3-ptxA1-prn2 or
9-fim3-1 and ptxP3-ptxA1-prn2 or 9-fim3-2.
Conclusions: Two emerging B. pertussis genotypes similar to isolates involved in worldwide epidemics were
detected in Perú. Low vaccine coverage (<50 %) and genetic divergence between the vaccine-producing strain
and the local isolates could contribute to this pertussal epidemic.
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Background
Whooping cough or pertussis is an acute respiratory dis-
ease caused mainly by the Gram-negative bacterium
Bordetella pertussis. Despite the introduction of massive
vaccination campaigns against pertussis in the fifties,
the disease remains a relatively common infection
with increasing incident rates reported in many countries
[1–4]. Thus, pertussis is considered at present a serious
public health problem in many countries, even including
those with high vaccination coverage [2, 5–7]. According
to the World-Health Organization (WHO), the incidence
rates of the disease have increased, reaching about
16 million cases per year in the world and involving
approximately 200,000 deaths, with 95 % of those cases
occurring in developing countries [1].
Several causes have been proposed to explain the resur-
gence of pertussis, with most being associated with current
vaccines: e. g., a waning vaccine-induced immunity, the
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switch from whole-cell vaccines (wP) to acellular vaccines
(aP), and an adaptation of the pathogen [8]. Published
data on the duration of immunity have estimated that
the immune protection after vaccination wanes after
4–12 years [9]. Recently, a meta-analysis of the duration
of protective immunity to pertussis after a routine
childhood immunization with aP indicated that the
average duration of protection from the aP vaccine is
about 3 years, assuming an 85 % vaccine efficacy [10].
The switch from the wP to the aP vaccine in many
countries for the schedule of primary vaccinations
resulting from concerns raised by reports of adverse
reactions associated with wP has apparently complicated
the pertussis epidemiologic situation [11, 12]. In that re-
gard, a case-control clinical study designed to assess the
risk of pertussis among adolescents and young adults
during the 2010 outbreak in California, USA revealed
that teenagers who had received four wP doses were
nearly six times less likely to have been diagnosed with
pertussis than those who had been given all aP vaccines
and nearly four times less likely than those who had
been given a mix of vaccines [13]. Waning immunity
also occurs after wP vaccination as well as after an episode
of pertussis [14].
Another possible cause of this present pertussis resur-
gence is the adaptation of B. pertussis to the immunity
induced by the current vaccines [15]. In fact, genomic
analyses of B. pertussis has revealed that a recent evolu-
tion of these bacteria has involved sweeps in which a
novel vaccine antigen allele arises and largely replaces
the previous dominant allele within that B. pertussis
population. In some—but not all—countries, the emer-
gence of allelic variants of the pertussis toxin–virulence-
factor (ptxA and ptxP), the pertactin (prn), and the
fimbriae (fim2 and fim3) genes matches with the disease
resurgences occurring there. More recently, isolates that
do not express one or more components of the acellular
vaccines—and in particular the antigenic virulence factor
pertactin—have emerged [16–19]. Increasing reports of
pertactin-negative isolates now point to the possible oc-
currence of a positive selective pressure involving the
suppression of pertactin expression, perhaps influenced
by the switch from the whole cell vaccine to the acellular
vaccine [20–23].
In Perú—a Latin American country that has used
wP in the schedule for the primary series of vaccina-
tions—the incidence of pertussis has increased from
an average of 0.68 cases per 100,000 inhabitants in
the 2007–2011 period, to 5.31 in 2012 [24]. In order
to find a possible explanation for the epidemiologic
resurgence of pertussis detected in Perú in 2012, we have
analyzed pertussis epidemiologic clinical information,
vaccine-related details, and genetic data from B. pertussis-
specific genomic analyses.
Methods
The surveillance of pertussis in Perú traditionally was
based mainly on clinical suspicion. The confirmation of
cases through laboratory results was limited because the
only diagnostic method available except for cultivation
was direct immunofluorescence until the introduction of
analysis by the real-time polymerase-chain reaction
(PCR) in 2012. The Instituto Nacional de Salud (INS, Perú)
currently uses the real-time–PCR method to diagnose
pertussis based on the detection of the specific DNA
sequences IS481, IS1001, and IS1002 in order to
recognize and distinguish between B. pertussis and B.
parapertussis [25].
Vaccination schedule
The current Peruvian vaccination program comprises three
doses of the pentavalent vaccine (a combination vaccine
containing the diphteric and tetanic toxoids, inactivated
cells of B. pertussis bacteria, a conjugated polysaccharide of
Haemophilus influenzae B type, and the surface antigen of
Hepatitis-B virus) at 2, 4, and 6 months of age. In addition,
the schedule includes two booster doses with the wP vac-
cine (DwPT: against diphtheria, pertussis, and tetanus) at
18 months and 4 years of age [26]. The pentavalent and
DwPT vaccines currently used in Perú are from The Serum
Institute of India.
Vaccine efficacy
Patients over 18 months of age were classified into two
groups: those who had completed the vaccination
scheme with 4–5 doses, and those who had received
fewer than 4 doses or no doses at all.
The attack rate [AR = (number of cases)/(popul-
tion at risk) × 100] and the relative risk (RR, the ratio of
the proportion of the treated cases to the proportion of
the nontreated cases) of pertussis after 4–5 doses com-
pared with the same parameter after fewer than 4 doses
or no doses were calculated.
The attack rate [AR = (number of cases)/(popul-
tion at risk) × 100] was first determined for both popula-
tions, and from those data the relative risk (RR = the ratio
of the proportion of the treated cases to the proportion of
the nontreated cases) was then calculated as the ratio of
those two attack rates. Finally, the percent vaccine efficacy
was computed by the following equation:
ð1½ARvaccinated=ARunvaccinatedÞ  100 ¼ ð1RRÞ  100
Population
A cross-sectional study was performed from May through
December 2012 in the Peruvian regions where pertussis
had been previously reported—namely, Ayacucho, Ucayali,
Lima, Huánuco, Cajamarca, Loreto, and Tacna [27]. The
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protocol of the study and informed consent-assent were
approved by the Research Committee and the Institutional
Ethics Committee from the INS.
Informed consent was signed by the parents or legal
guardians of children under 7 years old, whereas informed
assent was applied to children over 7 years old in addition
to the informed consent of their parents or guardians.
Samples were sent by the primary health-attention centers
of the regions after previous coordination with their
Regional Bureau of Health. The study involved 840 people
suspected of pertussi who conformed to the inclusion
criteria of the study.
Inclusion criteria
Patients of all ages hospitalized or receiving care with
persistent or paroxysmal cough, or people who had been
in contact with suspected cases of pertussis and signed
informed consent were included.
Exclusion criteria
Patients who exhibited signs and symptoms attributable
to chronic lung disease or a previously diagnosed re-
spiratory allergy were excluded. The inclusion-exclusion
criteria for the choice of research participants were blind
to socioeconomic status, skin color, religion, sexual pref-
erence, place of birth, or pregnancy status.
Following the identification of a clinical case, a case-
report form was completed with the information col-
lected during the patient and physician interviews. After
collection, specimens were routinely shipped to a labora-
tory for diagnosis. At the present time, the diagnosis is
performed by real-time PCR (introduced in 2012) and
bacterial cultivation.
Sample collection
The nasopharyngeal samples were collected with polyester
swabs having a flexible aluminum shaft (Puritan™, Fisher
Scientific) following the World-Health-Organization La-
boratory manual for pertussis [28] and the Pan-American
Health Organization Guide [29, 30]. The swab samples
were kept in vials with 500 μL of 0.9 % (w/v) sodium-
chloride solution. Clinical samples were collected in hospi-
tals and communities from Perú. Samples from patients
suspected of pertussis or epidemiologically related contacts
were sent together with their clinical and epidemiological
records and informed-consent forms to the Laboratory of
Biotechnology and Molecular Biology of the INS.
Real-time PCR on clinical samples
Genomic DNA from clinical samples was extracted from
200 μL of nasopharyngeal swab supernatant and purified
through the use of the Pure Link Genomic DNA Mini
Kit (Invitrogen) according to the manufacturer's recom-
mendations. The primers and probes used are listed in
Table 1. The protocol for molecular diagnosis was per-
formed as described previously [25]. For the PCR-
reaction mixture, Platinum Quantitative PCR SuperMix-
UDG (Invitrogen) was used. As a positive control for the
real-time PCR assays, genomic DNA from the B. pertus-
sis Tohama strain CIP 8132 was used.
B. pertussis isolation
Bacterial cultivation from the clinical samples was per-
formed in Regan Low-Agar medium supplemented with
cephalexin (40 μg/mL). The inoculated plates were incu-
bated for 10 days at 37 °C under aerobic conditions at
95 % humidity. Bacterial colonies having features charac-
teristic of Bordetella were confirmed as authentic by
real-time PCR and then genotyped by genetic sequen-
cing. A given culture was considered negative only after
remaining colony-free for 10 days. Confirmed B. pertus-
sis isolates were preserved in Brain-Heart Infusion broth
containing 30 % (v/v) glycerol at −80 °C and recovered
when needed for PFGE analysis.
Pulsed-field gel electrophoresis (PFGE) of B. pertussis
isolatess
PFGE analysis was performed according to references
[31, 32] with some modifications. The procedure stated
in brief: B. pertussis genomic DNA from 18 isolates in a
Table 1 Primers and probes used in this study
Gene or
sequence
Primer/probe sequence (5´–3´)a Purpose Reference
IS481 F: GCCGGATGAACACCCATAAG Diagnosis [25]
R: GCGATCAATTGCTGGACCAT
P: (FAM)-CGATTGACCTTCCTACGTC-(BHQ1)
IS1001 F: AATTGCTGCAAGCCAACCA Diagnosis [25]
R: CCAGAGCCGTTTGAGTTCGT
P: (HEX)-ACATAGACCGTCAGCAG-(BHQ2)
IS1002 F: CTAGGTCGAGCCCTTCTTGTTAAC Diagnosis [25]
R: GCGGGCAAGCCACTTGTA
P:(CY5)CATCGTCCAGTTCTGTTGCATCACCC-
(BHQ2)
ptxP F: AATCGTCCTGCTCAACCGCC Genotyping [33]
R: GGTATACGGTGGCGGGAGGA
ptxA F: CCCCTGCCATGGTGTGATC Genotyping [33]
R: TCAATTACCGGAGTTGGGCG
fim2 F: GCGCCGGGCCCTGCATGCAC Genotyping [33]
R: GGGGGGTTGGCGATTTCCAGTTCTC
fim3 F: GACCTGATATTCTGATGCCG Genotyping [33]
R: AAGGCTTGCCGGTTTTTTTTGG
Prn F: CAATGTCACGGTCCAA Genotyping [33]
R: GCAAGGTGATCGACAGGG
aF forward primer, R reverse primer; P probes for IS481, IS1001, and IS1002.
Fluorophores and quenchers are indicated at the 5´ and 3´ end of each
probe, respectively
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Seakem Gold Agarose-gel plug was extracted from the
bacteria with lysis buffer containing 1 % (w/v) sarcosyl
and 100 μg/mL proteinase K and the plug incubated in a
shaker bath at 56 °C for 16 h, and finally washed with
1X TE buffer six times at 50 °C in shaker bath. Genomic
DNA was digested with the restriction enzyme XbaI at
37 °C for 6 h. Finally, electrophoresis was performed in a
CHEF Mapper XA (Bio-Rad) apparatus for 23 h, with an
initial pulse of 5 s and a final pulse of 35 s. The analysis
and comparison of PFGE patterns were performed with
Gel Compar II software, version 5.1 (Applied Maths), on
the basis of the banding pattern of Salmonella Branderup
(H9812) DNA as the normalization standard.
Genotyping
DNA sequencing of B. pertussis genomic regions (ptxP,
ptxA, fim2, fim, and prn) was performed with the
primers listed in the Table 1, and according to the proto-
cols of reference [33]. The PCR products in an agarose gel
were purified with QIAquick Gel Extraction Kit (QIAGEN)
and the sequencing reaction carried out with the BigDye
Terminator v. 3.1 (Applied Biosystems) precipitated and
resuspended in Hi-Di formamide (Life Technologies). The
DNA sequencing was performed on an 3500XL Genetic
Analyzer (Applied Biosystems).
DNA sequences were analyzed by means of the Sequen-
cing Analysis and SeqScape Software (Applied Biosystems),
with respect to the sequence assembly, alignments, and
mutations. The sequences obtained were compared with
reference sequences included in Genbank.
Statistical analysis
We used the Internet Social Science Statistics Web
Server (www.socscistatistics.com/tests/chisquare) for statis-
tical comparisons between categorical variables by means
of chi-square (X2) tests. P values of ≤0.05 were considered
to indicate statistical significance.
Results
Perú pertussis outbreak in 2012
In 2012 an increase in pertussis cases was detected in
comparison to the number of cases registered during the
2009–2011 period (Fig. 1, Panel a). Throughout 2013,
Fig. 1 Weekly tally of pertussis-suspected cases according to year. Data obtained from the Peruvian Ministry of Health in 2012 (Panel a red curve,
2009; green curve, 2010; violet curve, 2011; azure curve, 2012) and 2014 (Panel b compressed curves for 2011 and 2012 next to the corresponding
curves for 2013 and 2014 with the years indicated above the curves). In the figures, the number of cases is plotted on the ordinate as a function of the
epidemiologic week on the abscissa
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the number of cases still remained higher than expected,
but then decreased in 2014 (Fig. 1, Panel b) [34].
Of the total of 840 pertussis-suspected cases reported
in 2012 in Perú (specifically in Ucayali, Ayacucho,
Loreto, Lima Tacna, Cajamarca, Huánuco, Huancavelica,
Piura), 390 (46.4 %) were male and 450 (53.6 %) female.
The age of the patients ranged from a few days after birth
to 83 years.
The vaccination status was available for 588 of the
patients: 464 (78.9 %) had had 0–3 pentavalent vac-
cine doses, and 124 (21.1 %) had received the primary
scheme plus 1 or 2 booster doses performed with the
DTwP vaccine (a total of 4 to 5 doses). Of the 408 patients
of 6 months of age, 206 had received at least 3 vaccine
doses (coverage: 50.5 %). Of the entire 840 surveyed cases,
191 (22.7 %) were positive in the assay by real-time PCR,
(Ct ≤35), while 19 were positive by both PCR and cultiva-
tion. Eighteen of the suspected bacterial cultures were
classified as B. pertussis and one as B. parapertussis
(Table 2). A higher pertussis incidence was detected in the
Peruvian regions of Ucayali, Loreto, Ayacucho, and Lima,
(of the 840 total cases 30.9, 22.5, 17.3, and 11.5 % respect-
ively; Table 3). The majority of the pertussis cases (60.7 %)
were reported from July through September 2012 (Table 3)
and detected in patients with fewer than 10 years of age
(78 %; Fig. 2, Panel a). Approximately 52 % of patients
Table 2 Characteristics of patients suspected of pertussis in
Perú during 2012
PCR-negative
n = 649 (%)
PCR-positive
n = 191 (%)
P value
Gender
Male 300 (46.2) 90 (47.1) 0.827
Female 349 (53.8) 101 (52.9)
Vaccine
Yes 265 (40.8) 82 (42.9) 0.81
No 182 (28.0) 59 (30.9)
No data 202 (31.1) 50 (26.2)
Vaccine dosesa
0–3 doses 331 (74.0) 133 (94.3) <0.00001*
4–5 doses 116 (26.0) 8 (5.7)
Clinical symptoms
Persistent cough 460 (70.9) 160 (83.8) 0.00037*
Paroxysmal cough 416 (64.1) 147 (77.0) 0.00089*
Vomiting after coughing 97 (14.9) 114 (59.7) <0.00001*
Stridor 177 (27.3) 71 (37.2) 0.0084*
Apnea 147 (22.7) 59 (30.9) 0.02
Cough (days)
1–6 132 (20.3) 43 (22.5) 0.51
7–12 93 (14.3) 46 (24.1) 0.0014*
13–15 70 (10.8) 39 (20.4) 0.0005*
> 20 68 (10.5) 12 (6.3) 0.082
No cough 286 (44.1) 51 (26.7)
Hospitalization
Yes 113 (17.4) 67 (35.1) <0.00001*
No 363 (55.9) 81 (42.4)
Not indicated 173 (26.7) 43 (22.5)
Antibiotica
Yes 197 (41.0) 100 (52.4) −
Azithromycin 29 (14.7) 30 (30.0) −
Erythromycin 56 (28.4) 25 (25.0) −
Penicillins 54 (27.4) 22 (22.0) −
Others 58 (29.4) 23 (23.0) −
Antibiotic (days of treatment)a −
1–3d 71 (10.9) 31 (16.2) −
4–6d 28 (4.3) 16 (8.4) −
≥ 7d 17 (2.6) 14 (7.3) −
Not indicated 81 (12.5) 39 (20.4) −
Etiology −
B. pertussis 0 (0) 145 (75.9) −
B. parapertussis 0 (0) 2 (1.0) −
Bordetella sp. 0 (0) 44 (23.0) −
*Chi-square (X2) test (p <0.05)
aPercentages were calculated only in the population known to have been
vaccinated or only in the recipients of an antibiotic
Of the total of 840 pertussis-suspected cases reported in 2012 in Perú, only 3
were treated with Cotrimoxazol
Table 3 Temporal and geographical distribution of patients
suspected of pertussis in Perú during 2012
PCR-negative
n = 649 (%)
PCR-positive
n = 191 (%)
Monthly pattern
May 29 (4.5) 6 (3.1)
June 43 (6.6) 25 (13.1)
July 129 (19.9) 45 (23.6)
August 139 (21.4) 37 (19.4)
September 139 (21.4) 34 (17.8)
October 129 (19.9) 18 (9.4)
November 38 (5.9) 25 (13.1)
December 3 (0.5) 1 (0.5)
Regional distribution
Ucayali 220 (33.9) 59 (30.9)
Ayacucho 201 (31.0) 33 (17.3)
Loreto 81 (12.5) 43 (22.5)
Lima 36 (5.5) 22 (11.5)
Tacna 56 (8.6) 17 (8.9)
Cajamarca 43 (6.6) 8 (4.2)
Huánuco 10 (1.5) 5 (2.6)
Huancavelica 2 (0.3) 2 (1.0)
Piura 0 (0) 2 (1.0)
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with pertussis had started antibiotic treatment before the
sample collection. The antibiotics used for the treatment
of those confirmed pertussis cases were: azithromycin
(for 30 % of the total), erythromycin (25 %), penicillins
(22 %), and others (23 %; Table 2).
The percentage of individuals with symptoms was
significantly higher in patients with a positive laboratory
result than in those who tested negative: persistent cough,
84 vs. 71 %, p = 0.00037; paroxysmal cough, 77 vs. 64 %,
p = 0.00089; vomiting after cough, 59 vs. 15 %, p <0.00001;
stridor, 37 vs. 27 %, p = 0.0084; 7–12 days of cough, 24 vs.
14 %, p = 0.0014; 13–15 days of cough, 24 vs. 14 %,
p = 0.0014 (Table 2). Conversely, no significant differences
were found for other symptoms—such as apnea or cough
duration of less than one week or more than two week-
s—or for gender or vaccine status without considering the
number of doses (Table 2).
With respect to the number of vaccine doses, the per-
centage of patients suspected of pertussis was signifi-
cantly higher in the group that had had 0–3 than in
those that had had 4–5 doses (94.3 vs. 5.7 %, p <0.00001;
cf. Table 4).
When pertussis was analyzed only in the group with
known vaccination records; 27.2, 8.4, 3.1, 4.2, and 0 %
had received 1, 2, and 3 doses, and those 3 along with
one or two vaccine boosters, respectively. Conversely,
the number of patients with diagnostic results that were
pertussis-negative increased with the number of vaccine
doses received (12.8, 13.6, 29.8, and 43.7 %, respectively;
cf. the blue bars of Fig. 2, Panel b). Table 4 shows the
distribution of pertussis-confirmed cases and non-cases
according to age and vaccination status. The majority of
those confirmed cases were detected in individuals of
fewer than 6 months of age as well those having had
A
B
Fig. 2 Distribution of pertussis cases detected in Perú during 2012 according to age (Panel a) or vaccination status of the patients (Panel b). In
the figures, the percentage of the total number of suspected cases that were PCR-negative (blue bars) and PCR-positive (red bars) is plotted on
the ordinates for each of the age ranges (Panel a) and for each of the vaccination doses (Panel b) indicated on the abscissas. The first
three doses correspond to the pentavalent vaccine and the booster dose to the DTwP vaccine. The asterisk (*) indicates a significant difference in the
chi-square test (p <0.00001)
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fewer than 3 doses of vaccine (Table 4). As expected,
non-cases received more vaccine doses than those con-
firmed cases.
For patients of more than 18 months of age, the AR
for pertussis per vaccination status proved to be 28 % in
those with 0–3 doses of vaccine and 6.4 % in those with
4–5 doses. Thus, the RR for patients with 4–5 doses
compared to those with fewer than 4 doses or no doses
at all was 0.23 (95 % confidence interval: 0.11–0.44), and
the vaccine effectiveness was 77 %.
Genomic analysis of B. pertussis isolates distributed
throughout Perú
B. pertussis clinical isolates (18) have been genetically
characterized by PFGE and the DNA sequencing of the
ptxP, ptxA, prn, fim2, and fim3 genetic loci. Among the
B. pertussis local isolates collected, 6 different PFGE-
profile patterns were identified (Fig. 3, PFGE patterns
P1–P6) and classified into 2 groups by means of the
algorithm unweighted-pair-group method with averaging
(UPGMA): the first group comprised the P1–P3 patterns
while the second the P4–P6. These two major B. pertussis
groups had a minimum of 87 % overall relatedness be-
tween them. B. pertussis Tohama strain (PFGE pattern
P7), with less than 80 % similarity to that of the clinical
isolates, was classified in a different PFGE group. The
P1–P3 group consisted in more isolates than the P4–P6
(i. e., 12 vs. 6), with P5 being the most highly represented
PFGE pattern (with 8 isolates; Fig. 3).
A gene-sequencing analysis of virulent factors has cat-
egorized B. pertussis isolates (n = 18) into two genotypes:
ptxP3-ptxA1-prn2 or 9-fim3-1, fim2-1 and ptxP3-ptxA1-
prn2 or 9-fim3-2, fim2-1. Twelve and 5 isolates pre-
sented prn2 along with the less frequent prn9 genotype
[35], respectively. As to the fim3 allele, 65 % was fim3-1
and 35 % fim3-2. We could not PCR-amplify either the
prn gene sequence from a single isolate (Bp898), nor the
the fim3 gene from another isolate (Bp503). As expected
the B. pertussis Tohama phase-I–strain genotype was
ptxP1-ptxA2-prn1-fim3-1.
Discussion
During 2012 in Perú, an increase in pertussis cases was
observed as reported by the National Surveillance Sys-
tem from the Peruvian Ministry of Health (Fig. 1) [34].
This increase could be attributable at least in part to the
introduction of a specific real-time PCR as a laboratory
diagnostic method instead of direct immunofluorescence
along with polyester swabs instead of the previously used
calcium-alginate swabs; which material, unlike polyester,
is known to inhibit the PCR reaction [36, 37]. Moreover,
the culture of B. pertussis was also reintroduced for use in
the diagnosis of pertussis in that same year. The outbreak
of pertussis detected at that time, could have also been
influenced by the contemporary pertussis epidemics re-
ported in neighboring countries [4, 30, 38]; which episodes
in some instances had started before 2012, and whose
detection had also been influenced by improvements in
surveillance and laboratory diagnosis [4, 30, 38].
The increase observed in the pertussis incidence in
2012 in this country was sustained in 2013, but then de-
creased in 2014 (Fig. 1, Panel b), probably as a result of
the reinforcement in pertussis immunization introduced
after 2012.
During 2012 most of the pertussis cases were confirmed
in patients younger than 3 months old (p <0.00001; Fig. 2,
Panel a). A large proportion of cases recorded in patients
younger than 3 months old was not unexpected since per-
tussis is most severe in that age group. Notwithstanding,
the number of cases registered in other age groups should
not be disregarded, especially during a pertussis epidemic
in the country. As expected, young unvaccinated infants,
or infants with an insufficient number of doses to confer
Table 4 Distribution of pertussis cases and no-cases by age and
vaccination in Perú, 2012
N° of vaccine doses
Age n (%) 0 1 2 3 4 5 NDb
Cases 0–<6 m 84 (10) 43 19 6 - - - 16
6–<12 m 13 (1.55) 2 - 8 - - - 3
1–<2 y 5 (0.6) 1 2 1 - - - 1
2–<4 y 9 (1.07) - 3 - - 3 - 3
4–<6 y 7 (0.83) - 2 - - 3 - 2
6–< 10 y 31 (3.69) 4 10 1 4 2 - 10
10–<15 y 18 (2.14) 1 10 - 2 - - 5
15–<20 y 6 (0.71) 3 2 - - - - 1
20–<30 y 8 (0.95) 1 2 - - - - 5
30–<40 y 6 (0.71) 3 2 - - - - 1
>40 y 4 (0.48) 1 - - - - - 3
Non-cases 0–<6 m 150 (17.86) 82 21 6 3 38
6–<12 m 54 (6.43) 15 1 11 17 - - 10
1–<2 y 54 (6.43) 5 1 2 15 10 - 21
2–<4 y 60 (7.14) 2 6 6 1 27 3 15
4–<6 y 64 (7.62) 6 2 1 5 19 22 9
6–< 10 y 91 (10.83) 11 1 3 23 25 4 24
10–<15 y 48 (5.71) 14 1 6 12 2 - 13
15–<20 y 13 (1.55) 3 - - - 1 - 9
20–<30 y 49 (5.83) 15 - - 2 1 - 31
30–<40 y 36 (4.29) 16 - - 1 1 - 18
>40 y 23 (2.74) 10 - - - 1 - 12
No data of age 7 (0.83) 3 1 - - - - 3
Total 840 (100) 241 86 51 85 95 29 253
aPentavalent vaccine for 1–3 doses plus DTwP for 4–5 booster doses
bND no data available from vaccine records
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adequate immunization, were more likely to contract
a severer disease, suffer complications, and require
hospitalization than older children and adults.
When patients with a positive diagnosis of pertussis
were grouped according to the number of vaccine doses,
the disease incidence in individuals who had received
fewer than 4 (the pentavalent wP alone or no vaccine)
was significantly higher than in those who had received
4–5 doses (pentavalent wP plus DTwP boosters; 94.3 vs.
5.7 %, p <0.00001; Table 2).
Another informative detail that became clear from the
analysis was the distribution of patients with pertussis-
positive diagnoses in relation to the age and vaccination
status of the patient (Table 4, Fig. 2). Of the total number
of studied cases, 69.4 % (583) had complete data regarding
the patient's age and vaccination status, while 21 % (177)
were younger than 6 months of age and had received
fewer than 3 vaccine doses. Approximately 11.9 % (100) of
the pertussis patients had had 3 or 4 vaccine doses and
were between 6 months and under 6 years of age, whereas
3.45 % (29) had received 5 doses of vaccine (Table 4).
Pertussis-vaccination coverage in some regions of Perú
was inadequate, and particularly with respect the first
dose of booster (ca. 50 %). The influence of vaccination
status on the incidence of pertussis was clearly demon-
strated in this study since a statistically higher pertussis-
attack rate was detected in individuals with 0–3 vaccine
doses at 28 vs. 6.4 % in individuals with 4–5 vaccine doses
(Fig. 2). These results once again underscore the need for
improving vaccination coverage in all regions of Perú, in
particular in those areas where poverty is prevalent.
As to the B. pertussis genotypes, a total of 6 different
PFGE profiles, referred to as P1 through P6 were charac-
terized in the clinical isolates. These profiles were classi-
fied into two major groups based on the criterion of a
degree of similarity higher than 0.70. Genetic differences
between bacteria detected and characterized throughout
the country and the B. pertussis Tohama-phase-I strain
were also observed (Fig. 3, sequences on the right). This
result is expected since that strain is an older laboratory-
adapted strain [39].
The predominant allelic variants that caused the Peru-
vian epidemic were: ptxP3-ptxA1-prn2 or 9-fim3-1 and
ptxP3-ptxA1-prn2 or 9-fim3-2 (Fig. 3), with ptxP3-ptxA1-
prn2-fim3-1 being the more prevalent genotype—it having
been designated by other authors as MT27a [40]. The re-
sults detected for fim alleles were similar to those reported
for the Argentine isolates fim2-1 (97 % of those studied),
and fim3-2 (76 %) [33].
The finding of the prn9 allele in 5 of the 18 total Peruvian
B. pertussis isolates was unexpected in view of the low fre-
quency previously reported for this allele [35]. Prn2 is the
most frequent allele present worldwide [15]. Nevertheless,
the existence of isolates with the allele prn9 instead of prn2
or prn3 were quite prevalent, while the variant ptxP3 corre-
sponded to the ptxP allele (Fig. 3). That the presence of
Fig. 3 PFGE profiles and genotypes of B. pertussis Peruvian clinical isolates. Geographic distribution of B. pertussis isolates is shown on the left of
the figure. The different individual patterns of pulse-field–gel-electrophoresis profiles in the center are indicated as P1 through P7. Genotyping
was performed by sequencing the pertussis-toxin promoter (ptxP), pertussis-toxin subunit A (ptxA), pertactin (prn), fimbriae 2 and fimbriae 3. The
classification of the allelic genotypes (indicated as Bp-strain numbers to the left of the sequences along with the country of origin)—III (blue), VI
(red group), and VII (green group)—is based on the van Gent et al. (2012) report [44]
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ptxP3 in the isolates was associated with an increased cap-
acity to spread and with an enhanced mortality rate is both
relevant and notable [41]. Nevertheless, that the complete
genetic background of ptxP3 strains in addition to the
ptxP3 must be likewise responsible for the better fitness of
B. pertussis is also noteworthy [42, 43].
Unfortunately we could not obtain the prn genetic se-
quence for the isolate designated Bp898 (Fig. 3) probably
because of mutations in the PCR-primer matching se-
quence or a deletion of the prn gene.
We must also stress that the B. pertussis isolates com-
prising group VI in Fig. 3 possessed a higher degree of
genetic similarity than those of group VII. This classifica-
tion of the allelic genotypes is based on the van Gent et al.
(2012) report [44]. Moreover, many isolates collected in
different regions of Perú presented the same P5 PFGE pat-
tern. This correspondence suggests a clonal distribution of
relatively few isolates throughout the entire country.
These findings are in accordance with previous reports
that revealed an increasing prevalence of the B. pertussis
genotype VI in the last decade [44].
Conclusions
Our results describe the pertussis epidemiologic situ-
ation in Perú and underscore the significance and ur-
gency of enhancing the vaccine coverage. The genotypes
of local circulating bacteria could be in part responsible
for the epidemic described in this country in 2012, but
molecular-genetic studies like those reported here should
be performed in order to continue to characterize the
pertussis-disease scenario in Perú.
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